Clinical Trial Imaging Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product and Service (Trial Design Consulting Services, Read Analysis Services, Operational Imaging Services, Imaging Software), By Modality (Magnetic Resonance Imaging, Computed Tomography, Ultrasound, Positron Emission Tomography, X-Ray, Echocardiography, Other Modalities), By End-User (Pharmaceutical & Biotechnology Companies, Medical Device Manufacturers, Academic and Government Research Institute), By Region, By Competition, 2020-2030F

Market Overview

The Global Clinical Trial Imaging Market, valued at USD 1.18 Billion in 2024, is projected to experience a CAGR of 7.30% to reach USD 1.80 Billion by 2030. The clinical trial imaging market encompasses the application of medical imaging modalities, such as Magnetic Resonance Imaging, Computed Tomography, and Positron Emission Tomography, to objectively assess the safety and efficacy of investigational therapeutics throughout clinical development. Primary drivers supporting this market's growth include sustained global research and development investments by pharmaceutical and biotechnology companies and an expanding pipeline of drug candidates, particularly in oncology and neurological disorders, which frequently rely on imaging as a critical endpoint. Regulatory requirements for quantifiable clinical trial endpoints further reinforce demand.

According to the European Organisation for Research and Treatment of Cancer (EORTC), in 2023, the organization was tracking 22,700 patients in follow-up and held over 215,000 patients in its clinical research databases, indicating substantial activity in oncology trials that heavily leverage imaging. A significant challenge impeding market expansion is the substantial capital expenditure required for sophisticated imaging equipment and the complexities associated with global image data management and standardization across numerous trial sites.

Key Market Drivers

The increasing global clinical trial volume is a fundamental driver for the clinical trial imaging market as pharmaceutical and biotechnology companies expand therapeutic pipelines. This expansion necessitates comprehensive imaging for drug safety and efficacy assessments, directly increasing demand for specialized services. This growth is evidenced by the rising number of registered studies; according to ClinicalTrials. gov, as of October 10, 2025, the number of registered studies reached 74,339. Concurrently, medical imaging technology advancements serve as a crucial market accelerant. Innovations like higher-field MRI and photon-counting CT enhance diagnostic precision and capabilities for trial evaluations. The integration of artificial intelligence in image analysis further refines data interpretation and optimizes workflows. For instance, according to the U. S. Food and Drug Administration, on May 13, 2024, an additional 191 AI/ML-enabled medical devices were approved, with 128 focused on radiology. These developments are essential for modern trials, where imaging is a critical endpoint.

This dynamic interplay of growing trial activity and technological progress fuels significant investment across the biopharmaceutical sector, highlighting imaging's vital role in drug development. This robust commitment to innovation is substantial within the global pharmaceutical industry. According to the International Federation of Innovative Pharmaceutical Industries' Facts & Figures 2024 report, by October 2024, more than 12,700 medicines were in various stages of development globally. This extensive pipeline, particularly in complex disease areas, relies profoundly on rigorous, reproducible data from clinical trial imaging, cementing its role in therapeutic discoveries.

Download Free Sample Report

Key Market Challenges

The substantial capital expenditure required for imaging equipment directly impedes the growth of the Global Clinical Trial Imaging Market. The high cost of acquiring and maintaining advanced medical imaging modalities, such as Magnetic Resonance Imaging or Positron Emission Tomography systems, places a significant financial burden on clinical trial sites and contract research organizations. This barrier limits the ability of many entities, particularly smaller or emerging research centers, to invest in the latest technology or expand their imaging capabilities. Consequently, the adoption of new imaging techniques and the establishment of new imaging-focused trial sites are constrained, impacting overall market expansion.

This financial challenge is further underscored by broader industry investment trends. According to AdvaMed, in 2022, equity financing for the medical technology sector, which includes imaging equipment, experienced a significant decline of 27% to USD 13.8 billion, marking its lowest point in seven years. This reduction in available equity capital makes it more difficult for organizations within the clinical trial imaging market to secure the necessary funds for substantial equipment purchases. The reliance on significant upfront investment for these essential diagnostic tools therefore directly restricts market growth by limiting access to critical infrastructure needed for advancing clinical trials.

Key Market Trends

The adoption of decentralized and hybrid clinical trial models is fundamentally reshaping operational strategies within the global clinical trial imaging market by enhancing patient accessibility and streamlining data collection. This approach integrates remote technologies such as telemedicine and wearable devices, reducing the need for extensive on-site patient visits and thereby broadening the geographic reach for participant recruitment. TransCelerate BioPharma's 2024 Annual Report indicates that both mature and newer initiatives have achieved 75% or higher adoption rates among their member companies in recent years, reflecting the increasing integration of flexible trial designs. This shift necessitates robust imaging infrastructure capable of handling diverse data formats from various remote sources while maintaining data integrity and standardization. For instance, TrialStat, a clinical research and data management technology company, was showcasing its cutting-edge Electronic Data Capture (EDC) Platform with an integrated Medical Imaging Workflow Platform at the Annual SoCalBio Investor & Partnering Conference in September 2025, highlighting solutions designed to advance imaging-based research in these evolving trial environments.

A significant trend driving the Global Clinical Trial Imaging Market is the intensified focus on precision medicine and the identification of novel imaging biomarkers. This involves leveraging advanced imaging techniques to pinpoint specific biological characteristics that can predict disease progression or therapeutic response, enabling more targeted and individualized treatments. According to a Novotech CRO whitepaper published in March 2024, the period from 2019 to 2023 saw over 10,000 ongoing global oncology trials initiated, with 30% specifically focused on precision oncology, demonstrating a substantial commitment to this area. The development of sophisticated analytical tools is crucial for extracting meaningful insights from complex imaging data in this context. Researchers at Mass General Brigham, for example, successfully harnessed foundation models to discover new cancer imaging biomarkers in May 2024, utilizing a comprehensive dataset of 11,467 abnormal radiological scans to identify patterns that could significantly improve early cancer detection and treatment. This trend underscores the critical role of advanced imaging in guiding therapeutic development for specific patient populations.

Segmental Insights

The Computed Tomography (CT) segment is experiencing rapid growth within the Global Clinical Trial Imaging Market due to its ability to provide detailed cross-sectional images crucial for effective disease assessment. This modality is widely adopted in clinical trials for oncology, cardiology, and neurology, enabling precise tracking of disease progression and treatment response. Advanced CT technologies, including iterative reconstruction and artificial intelligence integration, significantly enhance image quality and diagnostic capabilities, further driving its utility. Furthermore, increasing investments in pharmaceutical and biotechnology research and development, alongside the rising prevalence of chronic diseases, underpin the expanding demand for robust imaging solutions like CT in clinical studies. Regulatory frameworks, such as those established by the Food and Drug Administration, also support the standardized application of CT as a vital tool in evaluating drug efficacy.

Regional Insights

North America leads the global clinical trial imaging market due to several critical factors. The region benefits from substantial investments in pharmaceutical and biotechnology research and development, fostering a high volume of clinical trials. Furthermore, the presence of a robust ecosystem comprising numerous pharmaceutical companies, biotechnology firms, and Contract Research Organizations drives the demand for advanced imaging technologies. The regulatory environment, particularly the comprehensive guidelines set by the U. S. Food and Drug Administration (FDA) for imaging trials, ensures stringent quality and safety standards, thereby promoting confidence and facilitating the adoption of sophisticated imaging techniques in clinical research. This combination of robust R&D, advanced infrastructure, and a clear regulatory framework solidifies North America's dominant position.

Recent Developments

• In October 2025, RSNA Ventures and Rad AI announced a strategic partnership focused on advancing innovation in radiology and broader imaging technologies. This collaboration aimed to integrate RSNA’s peer-reviewed content directly into Rad AI’s solutions, which were utilized by numerous radiology practices and health systems across the U.S. The initiative was designed to furnish radiologists with immediate, trusted, and evidence-based insights within their daily workflows, thereby optimizing efficiency and improving patient care. This development supported the robust and accurate interpretation of medical imaging data, which is essential for effective clinical trials.

• In July 2024, GE HealthCare completed an agreement to acquire the medical artificial intelligence (AI) software business from Intelligent Ultrasound Group PLC. This acquisition, valued at approximately $51 million, was undertaken to integrate advanced AI solutions across GE HealthCare's entire ultrasound portfolio. The strategic move was designed to enhance efficiency and improve the ease of use for medical imaging professionals. This development significantly impacted the Global Clinical Trial Imaging Market by advancing AI-powered imaging tools, which are crucial for more precise and efficient data acquisition and analysis in ongoing clinical research.

• In June 2024, Calyx / Invicro announced a strategic partnership with BAMF Health, a global leader in molecular imaging and theranostics. This collaboration was formed with the objective of accelerating the clinical translation of radioligand therapies (RLT) and immuno-oncology (IO) agents. The partnership focused on addressing key challenges within the development of these advanced oncology treatments. By combining their specialized strengths, the companies aimed to elevate standards in oncology care and facilitate faster access to promising new treatments for patients through enhanced clinical imaging and development services.

• In March 2024, Calyx and Invicro combined their operations to establish a new global leader in providing medical imaging solutions and development services for the clinical research community. This union brought together extensive expertise, having supported nearly 12,000 clinical and research trials across all phases, including studies in oncology and the central nervous system. The strategic integration aimed to enhance scientific and operational support throughout the entire drug development lifecycle, from early discovery to post-marketing. The newly formed entity expanded its global presence, operating with approximately 2,000 employees across multiple international sites.

Key Market Players

• Clario Medical Imaging Inc
• Icon PLC
• Ixico PLC
• Koninklijke Philips N.V
• Medpace
• Navitas Clinical Research, Inc
• Parexel International Corporation
• ProScan Imaging
• Radiant Sage LLC
• Resonance Health

Report Scope:

In this report, the Global Clinical Trial Imaging Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Clinical Trial Imaging Market, By Product and Service:

o   Trial Design Consulting Services

o   Read Analysis Services

o   Operational Imaging Services

o   Imaging Software

• Clinical Trial Imaging Market, By Modality:

o   Magnetic Resonance Imaging

o   Computed Tomography

o   Ultrasound

o   Positron Emission Tomography

o   X-Ray

o   Echocardiography

o   Other Modalities

• Clinical Trial Imaging Market, By End User:

o   Pharmaceutical & Biotechnology Companies

o   Medical Device Manufacturers

o   Academic and Government Research Institute

• Clinical Trial Imaging Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Clinical Trial Imaging Market.

Available Customizations:

Global Clinical Trial Imaging Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Clinical Trial Imaging Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]